An open-label study of the effect of PEGASYS [peginterferon alfa-2a] on sustained virologic response in patients with chronic hepatitis C receiving ribavirin combination therapy.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 04 Jun 2010

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

04 Jun 2010 Additional trial locations (Bosnia and Herzegovina, Czech Republic, Slovakia) identified as reported by Roche record.
23 Feb 2010 Status changed from recruiting to completed as reported by Roche record.
20 Jun 2006 New trial record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com